⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRNX News
Crinetics Pharmaceuticals, Inc.
ViroMissile Appoints Michael G. Wood as Chief Business Officer
globenewswire.com
CRNX
ABBV
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CRNX
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
globenewswire.com
CRNX
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
globenewswire.com
CRNX
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
globenewswire.com
CRNX
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
globenewswire.com
CRNX
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
prnewswire.com
GTBP
ADCT
STRO
CRNX
TCRX
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
CRNX
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector
businesswire.com
CRNX
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
globenewswire.com
CRNX